The Developmental Research Program (DRP) of the Pacific Northwest (PNW) Prostate Cancer SPORE is designed to solicit, evaluate, and support innovative pilot projects in translational prostate cancer research. Projects funded under the DRP are intended to rapidly advance a new idea or concept that has the potential to substantially impact our understanding of prostate cancer, and ultimately influence the clinical management of this disease through improved prevention and treatment strategies. Since the inception of the PNW Prostate Cancer SPORE, the infrastructure of the DRP has established mechanisms to quickly respond to translational research opportunities within the PNW SPORE institutions that require support to advance hypotheses or confirm feasibility in order to justify larger resource investments. Developmental projects include research in basic science, clinical science, and population-based studies, and will continue to build collaborations between PNW SPORE sites and other institutions with SPOREs in prostate cancer. Developmental projects will be selected based on their potential to mature into translational research studies that will receive independent funding, either within our SPORE, or from philanthropic, foundation or government sources. The DRP is designed to attract both senior investigators with diverse scientific expertise and investigators new to translational prostate cancer research.

Public Health Relevance

Investments in early-stage innovative ideas are essential for ensuring that new concepts and approaches can be rapidly directed toward improving our understanding, prevention, and treatment of prostate cancer. Through the Developmental Research Program, the PNW SPORE environment will provide multidisciplinary resources to advance novel scientific ideas, continue an organized, rigorous, and consistent program to fund and promote early-stage projects, and cultivate the recruitment of new and established investigators in prostate cancer translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-12
Application #
8933582
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2002-09-19
Project End
2018-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$165,573
Indirect Cost
$63,739
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53
Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Plymate, Stephen R; Sharp, Adam; de Bono, Johann S (2018) Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol 4:1187-1188
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735

Showing the most recent 10 out of 400 publications